Artiva Biotherapeutics Announces Executive Reshuffle: New R&D Head, CFO Departs
ARTV has more than doubled off its 52-week low of $1.47.
Summary
Artiva Biotherapeutics announced a major executive reshuffle, including the departure of its CFO, the appointment of a new President and Head of R&D, and the CEO taking on interim financial officer duties.
Key Events · Executive and Board Changes · ARTV
-
CFO Thad Huston Departs
Thad Huston separated from his position as Chief Financial Officer, effective May 22, 2026, by mutual agreement. He will receive a severance package of approximately $135,000 and up to nine months of COBRA benefits.
-
Dr. Diego Miralles Appointed President & Head of R&D
Dr. Diego Miralles resigned from the Board of Directors to assume the role of President and Head of Research and Development. His compensation includes a $600,000 annual base salary and inducement equity awards of 232,500 stock options and 77,500 restricted stock units (RSUs).
-
CEO Fred Aslan Assumes Interim Financial Roles
Fred Aslan, M.D., the current Chief Executive Officer, has been appointed as the principal financial officer and principal accounting officer on an interim basis while the company searches for a new CFO.
-
President Fred Aslan Resigns from President Role
Dr. Fred Aslan resigned as President of the company but remains the Chief Executive Officer and a member of the Board, indicating a restructuring of executive responsibilities.
Analysis · ARTV · Life Sciences
This filing details a significant executive leadership restructuring. While the departure of the CFO creates a temporary gap in financial leadership, the appointment of a dedicated President and Head of Research and Development, especially one transitioning from the Board, is a strategic move for a biotech company following recent positive clinical data. The CEO stepping into interim financial roles provides continuity during the search for a new CFO.
At the time of this filing, ARTV was trading at $9.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $227.9M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.